BeOne Medicines AG (ONC) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes oncology medicines. The company generates revenue primarily through product sales of its approved cancer therapies, as well as collaboration agreements and licensing arrangements with pharmaceutical partners. Its ordinary shares are listed on The Stock Exchange of Hong Kong Limited (HKEx) under the ticker 06160, while American Depositary Shares provide U.S. investor access. The filing, a 10-K submitted February 26, 2026 (accession 000162828026011946), covers fiscal year operations under a Swiss incorporation structure with a par value of $0.0001 per ordinary share. BeOne Medicines competes in the global oncology therapeutics market, a sector characterized by high research and development costs, regulatory-driven barriers to entry, and intellectual property protection as the primary moat source.

Revenue model

Product sales of approved oncology therapies, supplemented by collaboration and licensing revenue from pharmaceutical partnership agreements.

Products and services

Oncology medicines; specific approved products and pipeline assets are not detailed in the available filing excerpts.

Customers and end markets

Oncology end market; specific customer types such as hospitals, specialty pharmacies, or payers are not detailed in the available filing excerpts.

Value-chain role

Drug developer and commercial-stage biopharmaceutical manufacturer focused on oncology.

Geographic exposure

Shares listed on The Stock Exchange of Hong Kong Limited (HKEx); U.S. ADS registration with the SEC. Specific revenue geographic breakdown not supported by available filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Stealth BioTherapeutics Corp